Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.
Apolipoprotein M Polymorphism Is a Novel Risk Factor for Dyslipidemia in Rheumatoid Arthritis: A Possible Link Between Disease Susceptibility and Dyslipidemia.
Park1, Yune-Jung, Lee1, Jung-Hwa, Yoon2, Hosung, Kim1, Daejun, Cho3, Chul-Soo, Kim1, Wan-Uk
The Catholic University of Korea, St. Vincent's Hospital, Suwon, South Korea
The Catholic University, Incheon, South Korea
The Catholic University of Korea, Seoul
Background/Purpose:
Chronic inflammatory diseases, including rheumatoid arthritis (RA), have been implicated in the increased risk of dyslipidemia. Apolipoprotein M (apoM) is a novel apolipoprotein predominantly associated with high-density lipoprotein cholesterol (HDL-C). In this study, we investigated the possible association of APOM polymorphism and dyslipidemia in Korean RA patients.
Methods:
A genome-wide association scan (GWAS) was performed 100 RA patients and 600 controls using Affymetrix SNP array 5.0. Two-hundred fifteen well-characterized RA patients, who provided complete genotyping, were evaluated for this cross-sectional study. Fasting lipid profile, disease activity in 28 joints, inflammatory markers, and radiographic severity using modified Sharp method were also assessed.
Results:
Through GWAS, APOM gene was identified as a novel SNP associated with RA (rs805297, odds ratio (OR)=2.28 [1.65–3.14], P<0.001). RA patients had increased frequency of A allele on apoM C-1065A compared to the controls (44.8 % versus 36.4 %, OR=1.40 [1.19–1.65], P<0.001). RA patients with APOM 1605 A carriers (CA+AA) had higher levels of total cholesterol and low-density lipoproteins, as well as lower levels of HDL-C and pre-b-HDL-C than those with CC genotype. After adjustment of gender, BMI, diabetes, medications, and inflammatory markers, APOM genotype was strongly associated with low HDL-C (OR=2.75 [1.17–6.5], P=0.021). Moreover, when subgroup analyses according to disease activity and Sharp score were performed, the association between APOM genotype and low HDL-C levels was still significant in all subgroups, indicating that APOM polymorphism may increase the risk of dyslipidemia, independent of disease activity and radiographic severity of RA.
Conclusion:
The APOM C-1605A polymorphism is associated with an increased risk for developing RA and low HDL-C levels in RA patients. Reduced HDL-C level is independent of disease activity and severity, but it is significantly influenced by APOM genotype. These findings suggest that a certain genetic factor itself for RA could be fundamentally linked to dyslipidemia, increasing the risk of atherosclerosis.
To cite this abstract, please use the following information:
Park, Yune-Jung, Lee, Jung-Hwa, Yoon, Hosung, Kim, Daejun, Cho, Chul-Soo, Kim, Wan-Uk; Apolipoprotein M Polymorphism Is a Novel Risk Factor for Dyslipidemia in Rheumatoid Arthritis: A Possible Link Between Disease Susceptibility and Dyslipidemia. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :2158
DOI:
